RAAS inhibitors do not increase the risk of COVID-19
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Link
http://www.nature.com/articles/s41569-020-0401-0.pdf
Reference5 articles.
1. Mancia, G. et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2006923 (2020)
2. Mehra, M. R. et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2007621 (2020)
3. Reynolds, H. R. et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2008975 (2020)
4. Mehta, N. et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1855 (2020)
5. de Abajo, F. J. et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet https://doi.org/10.1016/S0140-6736(20)31030-8 (2020)
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Acute and Post-Acute COVID-19 Cardiovascular Complications: A Comprehensive Review;Cardiovascular Drugs and Therapy;2023-05-20
2. Correlation between structural heart disease and cardiac SARS-CoV-2 manifestations;Communications Medicine;2022-11-11
3. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19;Critical Care Medicine;2022-07-27
4. 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards;Circulation: Cardiovascular Quality and Outcomes;2022-07
5. 2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19;Journal of the American College of Cardiology;2022-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3